PERCEPTIVE ADVISORS LLC - 18 Apr 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: 10%+ Owner
Issuer ticker: CRNX
Reported as of: 18 Apr 2022
Net transaction value: +$3,499,983
SEC form: 4
Accepted by SEC: 18 Apr 2022, 17:39:18 UTC
Prior SEC filing: 14 Apr 2022
Next SEC filing: 27 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member

Key filing fact

PERCEPTIVE ADVISORS LLC filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 18 Apr 2022.

Key facts

This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Apr 2022, 17:39.

Change

Previous filing in this sequence was filed on 14 Apr 2022.
Current net transaction value: +$3,499,983.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Purchase

Transaction value: $3,499,983
Shares: +157,515
Change %: +3.1%
Price: $22.22
Shares after: 5,321,032
Date: 18 Apr 2022
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.